Treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Mechanism of Action:
Fasenra binds to interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils, reducing their number in the blood and airways.
This helps to decrease airway inflammation and improve asthma symptoms.
Important Information:
Consult your doctor before use, especially if you have a history of allergic reactions to certain injections or medicines.
Inform your physician about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products.
Do not use Fasenra unless your doctor advises.
Notify your physician if you are pregnant, planning to have a baby, or are a nursing mother.
The medicine is not recommended for use in children under 18.
Store Fasenra in a refrigerator at (2°C-8°C). Do not freeze.
Administration:
Fasenra is administered as a subcutaneous injection (under the skin).
Your doctor, nurse, or other healthcare professional will show you how to inject the medicine.
The frequency and dosing may vary depending on the specific treatment regimen prescribed by a healthcare provider. It is usually given once every 4 to 8 weeks.
Safety Advice:
Pregnancy: Do not use Fasenra unless your doctor advises. Notify your physician if you are pregnant or planning to have a baby.
Breastfeeding: It is unknown whether Fasenra is safe to administer during breastfeeding. Inform your physician if you are a nursing mother.
Lungs: Fasenra is safe for patients with lung problems. Inform your physician if you have lung disease before starting the treatment.
Liver: It is unknown whether Fasenra is safe for patients with liver problems. Inform your physician if you have any liver disease before starting the treatment.
Alcohol: It is unknown whether consuming alcohol while taking Fasenra is safe or not. Consult your doctor for more information.
Driving: Some side effects of Fasenra may impair your ability to drive or operate machinery.
How is Fasenra 30mg Injection 1ml administered?
Fasenra 30mg Injection 1ml is administered as a subcutaneous injection (under the skin). The frequency and dosing may vary depending on the specific treatment regimen prescribed by a healthcare provider. It is usually given once every 4 to 8 weeks.
Is Fasenra 30mg Injection 1ml a cure for asthma?
Fasenra 30mg Injection 1ml is not a cure for asthma. It is a medication designed to help manage and control severe eosinophilic asthma by reducing airway inflammation and symptoms.
Can Fasenra 30mg Injection 1ml be used in children?
Fasenra 30mg Injection 1ml is approved for use in adolescents aged 12 years and older with severe eosinophilic asthma. Its safety and efficacy in younger children have not been established.
What formulations are available for Fasenra 30mg Injection 1ml?
Fasenra 30mg Injection 1ml is available in injection form. The specific formulation and dosing will depend on the individual's condition and the healthcare provider's recommendation.
Who should not take Fasenra 30mg Injection 1ml?
Fasenra 30mg Injection 1ml may not be suitable for everyone. Individuals with known hypersensitivity or allergy to it or its components should not use it. It is important to inform your physician of any other medical conditions or medications you are taking before starting the treatment.
Fact Box:
Molecule name: Benralizumab.
Therapeutic class: Anti-asthmatic agents.
Pharmacological class: Interleukin inhibitors.
Indications: Treatment of severe eosinophilic asthma.